Major questions facing the CF clinical and research community are whether the immune system in pwCF will age normally or whether this process is already accelerated and how new treatments, such as CFTR modulators, will affect immunosenescence and inflammaging as pwCF live longer. Here, CFTR is linked to cystic fibrosis.